CVL-936 / AbbVie - LARVOL DELTA

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects (clinicaltrials.gov) - P1; N=10; Terminated; Sponsor: Cerevel Therapeutics, LLC; N=27 ➔ 10; Trial completion date: Nov 2020 ➔ May 2020; Active, not recruiting ➔ Terminated; Trial primary completion date: Jun 2020 ➔ Mar 2020; Sufficient data has been obtained to meet current objectives

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Cerevel Therapeutics, LLC; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Cerevel Therapeutics initiates phase 1 clinical trial of CVL-936, an investigational medicine in development to treat substance use disorder (Businesswire) - "Cerevel Therapeutics...today announced that it has begun dosing healthy volunteers in a Phase 1 clinical trial of CVL-936, an orally-administered and potential first-in-class investigational therapy for the treatment of substance use disorder."

Trial status